Delving into the Latest Updates on Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Neoplasms

Respiratory Diseases

Recombinant protein

Biosimilar

Enzyme

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Endocrinology and Metabolic Disease	2
Nervous System Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Recombinant protein	1
Herbal medicine	1
Biosimilar	1
Enzyme	1

Top 5 Target	Count

Protein kinases	1
VDR(Vitamin D receptor)	1
PI3Kα x mTORC1 x mTORC2	1
PLG(Plasminogen)	1

The primary objective was to investigate the tolerability of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors. The secondary objective was to evaluate the pharmacokinetic characteristics of single and multiple intravenous infusions of recombinant human endostatin injection in Chinese patients with advanced solid tumors.

Start Date12 Dec 2016

Sponsor / Collaborator

Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

[+1]

CTR20140875

/ Not yet recruitingPhase 1

山茱萸总萜片Ⅰ期人体耐受性临床试验

[Translation] Phase I human tolerability clinical trial of Cornus officinalis total terpenoid tablets

通过对健康受试者进行山茱萸总萜片不同给药剂量的探索，考察人体的初步耐受性和安全性，为Ⅱ期临床试验提供安全的剂量范围。

[Translation]

By exploring different dosages of Cornus officinalis total terpenoid tablets on healthy subjects, the preliminary tolerance and safety of the human body were examined to provide a safe dosage range for Phase II clinical trials.

Start Date-

Sponsor / Collaborator

Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Login to view more data

100 Deals associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

2

1

Phase 3

Approved

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Citicoline Sodium	Brain Injuries More	Approved
Colecalciferol ( VDR )	Vitamin D Deficiency More	Approved
Reteplase biosimilar(Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.) ( PLG )	Myocardial Infarction More	Approved
YS-001 ( PI3Kα x mTORC1 x mTORC2 )	Advanced Malignant Solid Neoplasm More	Phase 1
Cornus officinalis Terpene Tablets	Early-onset type II diabetes More	Phase 1